Compounded tirzepatide for weight loss

Tirzepatide acts on two metabolic pathways instead of one. Here is how it works, what to expect, and who it is most appropriate for.

Last updated: May 4, 2026 Reviewed against: Current obesity-medicine and GLP-1 treatment guidelines Category: Medication

What is tirzepatide?

Tirzepatide is a once-weekly injectable medication that activates two gut hormone receptors — GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It is the active ingredient in Mounjaro and Zepbound. By acting on both pathways, tirzepatide tends to produce greater weight loss than GLP-1-only medications in head-to-head clinical trials.

How does tirzepatide work?

Tirzepatide engages two complementary metabolic systems:

GLP-1 activity reduces appetite, slows gastric emptying, and improves blood sugar control — the same pathway as semaglutide.
GIP activity appears to enhance insulin sensitivity, support fat metabolism, and amplify the appetite-reducing effect.

The combination produces a stronger satiety signal at lower nausea levels in many people, which is why average weight loss is typically higher.

Who is tirzepatide for?

Compounded tirzepatide may be appropriate for adults who:

Have a BMI of 30 or higher, or 27 or higher with weight-related conditions
Have plateaued or not responded sufficiently to a GLP-1-only medication like semaglutide
Want a more aggressive weight-loss timeline within a clinical context
Do not have contraindications (see safety section)

How is tirzepatide dosed?

Dosing is titrated up gradually:

Weeks 1–4: 2.5 mg once weekly
Weeks 5–8: 5 mg once weekly
Weeks 9–12: 7.5 mg once weekly
Week 13+: 10 mg, then 12.5 mg, then up to 15 mg as tolerated

Your clinician personalizes titration based on response and tolerability.

Expected results

In the SURMOUNT-1 trial, adults on the 15 mg dose of branded tirzepatide lost an average of 20.9% of body weight at 72 weeks. Many participants achieved ≥25% weight loss. Real-world results depend on dose, consistency, nutrition, and activity.

Common side effects

Side effects are similar to semaglutide and include:

Nausea, especially during dose increases
Constipation or diarrhea
Fatigue, headache, or burping
Decreased appetite (intended)

Serious but rare risks include pancreatitis, gallbladder issues, kidney problems, and thyroid C-cell tumors. Tirzepatide carries a boxed warning for medullary thyroid carcinoma.

Safety and contraindications

Tirzepatide should not be used by people with a personal or family history of MTC or MEN 2, history of pancreatitis, severe gastrointestinal disease, or during pregnancy and breastfeeding. Your clinician screens for all of these during evaluation.

Frequently asked questions

Is tirzepatide stronger than semaglutide?

In clinical trials, tirzepatide produced greater average weight loss than semaglutide at maximum doses. In SURMOUNT-1, participants on the highest tirzepatide dose lost about 20.9% of body weight over 72 weeks, versus about 14.9% over 68 weeks on semaglutide in STEP 1. Tirzepatide activates both GIP and GLP-1 receptors, which may explain the larger average effect. Individual response varies; some people respond better to one medication than the other, and side-effect tolerance often matters as much as average efficacy when choosing.

Can I switch from semaglutide to tirzepatide?

Yes. Many members start on semaglutide and switch to tirzepatide for stronger results or to break through a plateau. Your clinician coordinates the transition and adjusts dosing — typically starting tirzepatide at a low dose and titrating up rather than swapping milligram-for-milligram, since the two medications use different dosing scales. Most members complete the switch without a gap in treatment.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

Compounded tirzepatide contains the same active ingredient as the brand-name versions, but it is a different product. It is prepared by state-licensed U.S. compounding pharmacies rather than the brand manufacturer, and compounded medications are not reviewed by the FDA for safety, quality, or efficacy. A U.S.-licensed clinician evaluates your health history before any prescription is issued.

Will I have to be on it forever?

Tirzepatide works while you take it. Many members transition to a lower maintenance dose after reaching their target weight. Some discontinue with strong lifestyle reinforcement; others continue long-term, similar to other chronic-condition medications. Clinical follow-up studies have shown that weight regain is common after stopping GLP-1-class medications without a maintenance plan, which is why dose and duration decisions are made with your clinician at regular check-ins rather than on a fixed schedule.

Ready when you are.

Take a 90-second medical intake. Your clinician reviews it and prescribes only when clinically appropriate.

See treatment plans →

References & sources

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205–216. nejm.org/doi/full/10.1056/NEJMoa2206038
Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM. 2021;385:503–515. nejm.org/doi/full/10.1056/NEJMoa2107519
U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. accessdata.fda.gov (Drugs@FDA: Zepbound)

Editorial standards & medical oversight

This educational content follows WeightlessRx clinical content standards and is reviewed for accuracy against current obesity-medicine and GLP-1 treatment guidelines, including FDA prescribing information, the American Association of Clinical Endocrinology (AACE) obesity guideline, and peer-reviewed clinical literature. Information is educational and is not medical advice. Treatment eligibility is determined only after a U.S.-licensed clinician in our third-party provider network reviews your intake and medical history. Read our full medical review policy →